uniQure (NASDAQ:QURE) Upgraded to “Sell” at StockNews.com

StockNews.com upgraded shares of uniQure (NASDAQ:QURE) to a sell rating in a research note published on Wednesday.

A number of other research firms also recently issued reports on QURE. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price target on shares of uniQure in a research report on Tuesday, January 21st. Cantor Fitzgerald increased their target price on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 10th. Leerink Partners lifted their price target on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, Stifel Nicolaus raised their price objective on uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 16th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $40.00.

uniQure Stock Performance

Shares of QURE opened at $16.13 on Wednesday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The company’s 50 day simple moving average is $14.29 and its 200 day simple moving average is $9.09.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. As a group, research analysts forecast that uniQure will post -3.75 earnings per share for the current year.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in QURE. China Universal Asset Management Co. Ltd. grew its position in shares of uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 969 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in uniQure during the 4th quarter valued at $88,000. Geode Capital Management LLC raised its stake in uniQure by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after acquiring an additional 6,362 shares in the last quarter. RTW Investments LP acquired a new position in uniQure during the 3rd quarter worth $49,000. Finally, Atria Investments Inc acquired a new position in shares of uniQure during the third quarter valued at $53,000. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.